Intersect ENT, Inc. (XENT)
(Delayed Data from NSDQ)
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Implied Volatility Surging for Intersect ENT (XENT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.
Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS
by Zacks Equity Research
This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.
Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss
by Zacks Equity Research
Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -20.00% and 0.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Intersect ENT (XENT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Intersect ENT
by Zacks Equity Research
Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Intersect Posts Preliminary Q1 Results, Withdraws '20 View
by Zacks Equity Research
Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.
Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Intersect ENT Down on Low Propel Sales, Pricing Pressure
by Zacks Equity Research
Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.
Implied Volatility Surging for Intersect ENT (XENT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.
Intersect ENT (XENT) Reports Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the fourth quarter of 2019.
Intersect ENT (XENT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of 28.57% and 2.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
New Product Suite Boosts Intersect ENT Despite Cost Concerns
by Zacks Equity Research
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
by Zacks Equity Research
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
by Zacks Equity Research
Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.
Here's Why You Should Hold on to Intersect ENT (XENT) for Now
by Zacks Equity Research
Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes
by Zacks Equity Research
Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.
Intersect ENT (XENT) Grows on Innovation Despite Cost Woes
by Zacks Equity Research
The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.
Why Is Intersect ENT (XENT) Up 21.7% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates
by Zacks Equity Research
Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.
Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -2.50% and -0.73%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.